Savara presented new data from pivotal phase 3 impala-2 trial of molgramostim inhalation solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at american thoracic society conference (ats) 2025

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ats international conference 2025. data presented were from the phase 3 impala-2 clinical trial of molgramostim in apap and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with apap. ats 2025 posters poster ti.
SVRA Ratings Summary
SVRA Quant Ranking